Pfizer Indiplon “Refuse To File” For eNDA May Stem From Shift In FDA Oversight

FDA's shift of responsibilities for Pfizer/Neurocrine's insomnia drug indiplon between review divisions may have led to the agency's delay in accepting the NDA